Orthofix Medical (NASDAQ:OFIX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of Orthofix Medical (NASDAQ:OFIX - Free Report) from a hold rating to a sell rating in a report published on Friday morning.

Other equities analysts have also issued reports about the stock. JMP Securities reaffirmed a "market perform" rating on shares of Orthofix Medical in a report on Friday, June 6th. Barrington Research raised Orthofix Medical to a "strong-buy" rating and set a $16.00 price objective for the company in a research report on Monday, June 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $21.50.

Orthofix Medical Stock Up 0.5%

Shares of Orthofix Medical stock traded up $0.05 on Friday, reaching $11.09. The stock had a trading volume of 999,465 shares, compared to its average volume of 287,150. The company has a quick ratio of 1.50, a current ratio of 2.71 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $434.51 million, a P/E ratio of -3.01 and a beta of 0.80. The company has a 50 day moving average price of $11.85 and a 200 day moving average price of $15.24. Orthofix Medical has a 1 year low of $10.24 and a 1 year high of $20.73.

Insiders Place Their Bets

In other news, CEO Massimo Calafiore purchased 10,000 shares of the stock in a transaction on Friday, May 9th. The stock was bought at an average price of $12.54 per share, with a total value of $125,400.00. Following the transaction, the chief executive officer now owns 234,603 shares in the company, valued at $2,941,921.62. The trade was a 4.45% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Aviva Mcpherron sold 3,728 shares of the business's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total value of $39,181.28. Following the sale, the insider now owns 46,322 shares in the company, valued at approximately $486,844.22. The trade was a 7.45% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 112,250 shares of company stock valued at $1,380,970 and have sold 7,620 shares valued at $91,168. 1.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Orthofix Medical

A number of institutional investors and hedge funds have recently modified their holdings of OFIX. Lazard Asset Management LLC acquired a new stake in Orthofix Medical during the 4th quarter valued at approximately $45,000. US Bancorp DE lifted its position in Orthofix Medical by 684.6% during the first quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock valued at $93,000 after purchasing an additional 4,950 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Orthofix Medical during the fourth quarter valued at $112,000. Tower Research Capital LLC TRC grew its position in Orthofix Medical by 120.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock worth $148,000 after purchasing an additional 4,627 shares during the period. Finally, Strs Ohio purchased a new position in shares of Orthofix Medical during the 1st quarter valued at about $150,000. Institutional investors and hedge funds own 89.76% of the company's stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.